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ABSTRACT
The widespread use of Cas12a (formerly Cpf1) nu-
cleases for genome engineering is limited by their
requirement for a rather long TTTV protospacer ad-
jacent motif (PAM) sequence. Here we have aimed
to loosen these PAM constraints and have gener-
ated new PAM mutant variants of the four Cas12a
orthologs that are active in mammalian and plant
cells, by combining the mutations of their corre-
sponding RR and RVR variants with altered PAM
specificities. LbCas12a-RVRR showing the highest
activity was selected for an in-depth characterization
of its PAM preferences in mammalian cells, using a
plasmid-based assay. The consensus PAM sequence
of LbCas12a-RVRR resembles a TNTN motif, but also
includes TACV, TTCV CTCV and CCCV. The D156R
mutation in improved LbCas12a (impLbCas12a) was
found to further increase the activity of that variant in
a PAM-dependent manner. Due to the overlapping but
still different PAM preferences of impLbCas12a and
the recently reported enAsCas12a variant, they com-
plement each other to provide increased efficiency
for genome editing and transcriptome modulating
applications.
INTRODUCTION
The identification and characterization of novel CRISPR–
Cas systems expand the repertoire of effector proteins that
can be used for gene, epigenome and base editing applica-
tions in eukaryotic cells (1,2). Beside the commonly used
SpCas9, many other Cas effector nucleases with distinct
properties have been successfully repurposed for genome
engineering tasks (3–5). Among these several unique fea-
tures highlight the Cas12a (formerly Cpf1) protein fam-
ily that involves As- (Acidaminococcus sp.) and Lb- (Lach-
nospiraceae bacterium) Cas12a nucleases (3). These features
include: (i) the utilization of a single, shorter crRNA; (ii)
the recognition of T-rich PAM sequences; (iii) cleaving the
target DNA at a PAM distal position and (iv) generating
protruding DNA ends upon cleavage, as well as (v) having
indiscriminate single stranded DNAse activity upon target
binding (3,6). However, the most significant advantage of
Cas12a nucleases is their ribonuclease activity which allows
them to process their own crRNA from a longer precursor
(3,7). This latter characteristic greatly simplifies their use
for multiplex gene editing, transcription modulation and
imaging, which tasks typically require simultaneous target-
ing of more sequences for efficient operation (8,9). In spite
of these favourable features, their broader application is lim-
ited by the relatively rare occurrence of their long TTTV
PAM sequence in mammalian genomes. The theoretically
calculated frequency of the TTTV PAM motif in DNA se-
quences is 3/256, a number which is considerably smaller
than the 16/256 frequency of the canonical NGG motif of
SpCas9.
Searching for a robust Cas12a nuclease preferring a more
frequent PAM sequence is still ongoing. Two Cas12a or-
thologues, namely Fn- (Francisella novicidaU112) andMb-
Cas12a (Moraxella bovoculi 237), were reported to require
NTTN PAM sequences in vitro (3); however, this find-
ing has been confuted, and the PAM sequence was found
to be stricter in mammalian cells (10,11). Another ap-
proach for loosening the PAM constrains of Cas12a or-
thologues is the generation of mutant variants with al-
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tered PAM preferences. Such mutant variants, AsCas12a-
RVR and AsCas12a-RR were generated, and were shown
to exhibit TATV and TYCV PAM preferences, respectively
(12,13). It was shown that these mutants also preserved
the canonical TTTV PAM preference of the AsCas12a-WT
in mammalian cells (10,12,13), thus they are characterized
by a PAM frequency of 6/256 (RVR) or 9/256 (RR), re-
spectively. Mutants analogous to the other (Lb-, Fn-, Mb-)
Cas12a orthologues were also generated, and were found to
exhibit similarly loosened PAM constrains, but slightly dif-
ferent target preferences. In all orthologues, the RVR and
RRmutations seem to alter the preferences primarily at the
third and second position of the PAM sequence (10). When
multiplexing with Cas12a, a single variant that can access
all PAM sequences available for the WT and the RVR and
RRmutants would be advantageous. Being inspired by this
challenge, we have combined these mutations in order to
create a more potent Cas12a nuclease variant.
MATERIALS AND METHODS
Materials
Restriction enzymes, Taq DNA polymerase (recombinant),
Platinum Taq DNA polymerase and T4 ligase were pur-
chased from Thermo Fischer Scientific. DNA oligonu-
cleotides were acquired from Sigma-Aldrich. All DNA con-
structs were verified by Sanger sequencing (Microsynth
AG). Plasmids were purified with the GenElute HP Plas-
midMiniprep kit (Sigma-Aldrich). Q5 polymerase was pur-
chased from New England BioLabs Inc. Dulbecco’s mod-
ified Eagle’s Medium, foetal bovine serum, penicillin and
streptomycin were acquired from Thermo Fisher Scien-
tific. 2 mm electroporation cuvettes were acquired fromCell
Projects Ltd. and Bioruptor 0.5 ml Microtubes for DNA
Shearing from Diagenode. Agencourt AMPure XP beads
were purchased from Beckman Coulter Inc. T4 DNA ligase
(for GUIDE-seq) and end-repair mix were acquired from
Enzymatics Inc. KAPA universal qPCR Master Mix was
purchased from KAPA Biosystems.
The following plasmids were gifts from Jia Chen (Ad-
dgene number: pCMV-dCpf1-BE#107685) (14), fromFeng
Zhang (Addgene number: pcDNA3.1-hLbCpf1 #69988,
pcDNA3.1-hAsCpf1 #69982) (3) and from Ron Vale
(Addgene number: pHRdSV40-scFv-GCN4-sfGFP-VP64-
GB1-NLS #60904) (15).
Plasmid construction
Vectors were constructed using standard molecular biology
techniques. For details see Supplemental File 1––Plasmid
Construction and Supplementary Table S1. The sequences
of DNA oligonucleotides utilized in this study are listed in
Supplementary File 2. Deposited plasmids are summarized
in Supplementary File 1––Supplementary Table S2.
Cell culturing
N2a (Neuro-2a mouse neuroblastoma cells, ATCC – CCL-
131), HEK293 (293 H, Gibco), HEK293.EFGFP and
HEK293.clover cells were grown at 37◦C in a humidi-
fied atmosphere of 5% CO2 content in high glucose Dul-
becco’s modified Eagle’s medium (DMEM) supplemented
with 10% heat inactivated foetal bovine serum, 4 mM L-
glutamine (Gibco), 100 units/ml penicillin and 100 g/ml
streptomycin.
HEK293.EGFP cells were generated, maintained and
transfected as described in reference (16). HEK293.clover
cells were generated as follows: a modified clover sequence
was inserted after the ATG of human prion protein cod-
ing sequence with a self-cleaving donor plasmid by NHEJ-
knock-in (17). The sequence of the inserted clover sequence
is given in Supplementary File 1.
GFxFP assay
The modified GFxFP assay was carried out as described
in reference (10,18). Spacer sequences and vectors used are
listed in Supplementary File 2.
Cells were seeded onto 48-well plates a day before trans-
fection at a density of 3 × 104 cells/well. The next day, at
around 40% confluence, cells were transfected with plas-
mid constructs using Jetfect reagent (Biospiral-2006 Ltd.),
briefly as follows: 250 ng total plasmid DNA (2 ng GFxFP
plasmid, 124 ng crRNA and nuclease expression plasmid,
and 124 ng mCherry expression plasmid to monitor the
transfection efficiency) and 1 l Jetfect were mixed in 50
l serum free DMEM and the mixture was incubated for
30 min at room temperature prior being added to cells.
Three parallel transfections were made from each sam-
ple. Cells were analysed by flow cytometry two days post-
transfection. TheEGFP signal was analysed in themCherry
positive population. Background fluorescence was deter-
mined by using a crRNA-less, inactive LbCas12a nucle-
ase expression vector as negative control and this back-
ground value was subtracted from each sample. Three par-
allel transfections were made for each case. Activities of the
Cas12a-WTnucleases on targets with TTTCPAMsequence
are counted as 100%.
Disruption assay
Disruption assay was carried out as described in reference
(10). Spacer sequences and vectors used are listed in Sup-
plementary File 2.
All EGFP disruption experiments were conducted on
HEK293.EGFP or HEK293.clover cells. Cells were plated
one day prior to transfection on 48-well plates at a density
of∼25 000–30 000 cells/well. Cells were co-transfected with
two types of plasmids: Cas12a variant expression plasmid
(137 ng) and crRNA and mCherry coding plasmid (97 ng)
using 1 l Jetfect reagent per well in 48-well plates. Trans-
fected cells were analysed six days post-transfection by flow
cytometry. For control an inactive LbCas12a expressing nu-
clease vector was used. Disruption activities of the nucle-
ases were calculated as follows: 1 – (sample GFP % / av-
erage GFP % of negative controls). Transfection efficiency
was calculated via mCherry expressing cells. Transfections
were performed in triplicate.
Base editor assay
Base-editor assay was carried out as follows: HEK293 cells
were seeded onto 48-well plates one day before transfection
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at a density of 1 × 104 cells/well. The next day, at around
25% confluence, cells were transfected with plasmid con-
structs using Jetfect reagent, briefly as follows: 350 ng to-
tal plasmid DNA (145 ng crRNA and mCherry expression
plasmid, plus 205 ng nuclease expression plasmid) and 1.5
l Jetfect reagent were mixed in 50 l serum free DMEM,
and the mixture was incubated for 30 min at room tem-
perature prior being added to cells. Three parallel trans-
fections were made from each sample. Transfection effi-
ciency was analysed by flow cytometry seven days post-
transfection via mCherry fluorescence. Next, cells were cen-
trifuged at 100 g for 10 min and genomic DNA was puri-
fied according to the Puregene DNA Purification protocol
(Gentra systems). PCRprimers used to amplify on- and off-
target genomic sequences are listed in Supplementary File
2. PCR products were purified by the Nucleospin Gel Ex-
tract Kit (Macherey-Nagel) and sent for Sanger sequencing
(Microsynth). Sequencing data was analysed by EditR (19).
Spacer sequences and vectors used are listed in Supplemen-
tary File 2.
Flow cytometry
Flow cytometry analysis was carried out on an Attune
Acoustic Focusing Cytometer (Applied Biosystems by Life
Technologies). For data analysis the Attune Cytometric
Software was used. In all experiments, a total of 10 000
viable single cells were acquired and were gated based on
side and forward light-scatter parameters. Cells expressing
EGFP and mCherry from a control plasmid were used to
adjust the parameters for the identification of EGFP and
mCherry positive cells in the samples. The EGFP signal was
detected using a 488 nm diode laser for excitation and a
530/30 nm filter for emission. The mCherry signal was de-
tected using a 561 nmdiode laser for excitation and a 620/15
nm filter for emission.
Next generation sequencing
HEK293 cells were seeded onto 48-well plates one day be-
fore transfection at a density of 1 × 104 cells/well. The next
day, at ∼25% confluence, cells were transfected with plas-
mid constructs using Jetfect reagent (Biospiral-2006. Ltd.),
briefly as follows: 234 ng total plasmid DNA (97 ng crRNA
and mCherry expression plasmid, plus 137 ng nuclease ex-
pression plasmid) and 1 l Jetfect reagent were mixed in
50 l serum free DMEM, and the mixture was incubated
for 30 min at room temperature prior to being added to
cells. Three parallel transfections weremade from each sam-
ple. Transfection efficiency was analysed by flow cytometry
5 days post-transfection via mCherry fluorescence. Next,
cells were centrifuged at 100 g for 10min and genomicDNA
was purified according to the Puregene DNA Purification
protocol (Gentra systems). Amplicons for deep sequencing
were generated in two rounds of PCR using Q5 high-fidelity
polymerase to attach Illumina handles. The first step PCR
primers used to amplify target genomic sequences are listed
in reference (10). After being quantified with the Qubit ds-
DNAHSAssay kit (Invitrogen), PCRproducts were pooled
for deep sequencing. Sequencing on an Illumina Miseq in-
strument was performed by ATGandCo Ltd. Indels were
counted computationally among reads thatmatched at least
75% to the first 20 bp of the reference amplicon. Indels and
mismatches were searched at ±60 bp around the cut site.
For each sample, the indel frequency was determined as
(number of reads with an indel)/(number of total reads).
The following software were used: BBMap 38.08, sam-
tools 1.8, BioPython 1.71, PySam 0.13. SRA accession: PR-
JNA590635. Spacer sequences and vectors used are listed in
Supplementary File 2. NGS raw data are available in Sup-
plementary File 3.
GUIDE-seq
GUIDE-seq experiments were performed with LbCas12a-
WT and LbCas12a-RVRR for seven different crRNAs.
Briefly, 3 × 106 HEK293.EGFP cells were transfected with
2.6 g of LbCas12a variant expressing plasmid and 1.9 g
of mCherry and crRNA coding plasmid. 100 pmol of the
dsODN containing phosphorothioate bonds at both ends
[according to the original GUIDE-seq protocol (20)] was
mixed with 100 l home-made nucleofection solution and
was added to the plasmids, and it was electroporated as de-
scribed inVriend et al. (21) usingNucleofector (Lonza) with
A23 program and 2 mm electroporation cuvettes. Trans-
fected cells were analysed ∼72 h post-transfection by flow
cytometry. Cells were then centrifuged at 1000 g for 10
min, and genomic DNA was purified according to the
PuregeneDNAPurification protocol (Gentra systems). Ge-
nomic DNA was sheared with BioraptorPlus (Diagenode)
to 550 bp in average. Sample libraries were assembled as
previously described (20) and sequenced on an Illumina
MiSeq instrument by ATGandCo Ltd. Data were analysed
using the open-source guideseq software (version 1.1) (22).
Consolidated reads were mapped to the human reference
genome GrCh37 supplemented with the integrated EGFP
sequence. Upon identification of the genomic regions inte-
grating double-stranded oligodeoxynucleotides (dsODNs)
in aligned data, off-target sites were retained when no more
than seven mismatches compared to the on-target site were
present and when they were absent in the background con-
trols. Visualization of aligned off-target sites are provided as
a color-coded sequence grid. Further details are available
in Supplementary File 4. SRA accession: PRJNA590635.
Spacer sequences and vectors used are listed in Supplemen-
tary File 2.
TIDE
Tracking of Indels by DEcomposition (TIDE) method (23)
was applied for analysing mutations and determining their
frequency in a cell population using different crRNAs and
LbCas12a variants. From the isolated genomic DNA PCR
was conducted with Q5 High-Fidelity DNA Polymerase in
triplicates (for PCR primer details, see Supplementary File
4). Genomic PCR products were gel excised via NucleoSpin
Gel and PCR Clean-up kit and the purified products were
Sanger sequenced. Indel efficiencies were analysed by TIDE
webtool (https://tide.nki.nl/) by comparing Cas12a treated
and control samples.
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Statistical analysis
Differences between LbCas12a variants were tested by Stu-
dent’s t test for paired-samples. Normality of the data and
of the differences were tested by Shapiro–Wilk Normality
Test. Statistical tests were performed on data including all
parallel sample points, using the IBM SPSS version 20 soft-
ware.
Upregulation, RT-PCR
N2a cells were seeded onto 6-well plates one day before
transfection at a density of 2 × 105 cells/well. The next
day, at ∼25% confluence, cells were transfected with plas-
mid constructs using Turbofect reagent (Thermo Fischer
Scientific), briefly as follows: 4000 ng total plasmid DNA
(1,200 ng crRNAandmCherry expression plasmid, 1200 ng
scFv-BFP-VP64 and 1600 ng dead nuclease-SunTag plas-
mid) and 6l Turbofect reagent were mixed in 400l serum
free DMEM, and the mixture was incubated for 30 min at
room temperature prior to being added to the cells. Three
parallel transfections were made from each sample. Cells
were harvested 2 days post-transfection. A small propor-
tion was used to measure transfection efficiency by flow
cytometry utilising mCherry and BFP fluorescence. The
rest of the cells were centrifuged at 100 g for 5 minutes,
and total RNA was extracted using RNAzol-RT (Sigma-
Aldrich). Genomic DNA contamination was digested by
DNAseI (Thermo Fischer Scientific). After DNAseI inac-
tivation, RNA was purified using Nucleospin RNA Clean-
up XS (Macherey-Nagel). Reverse transcription was per-
formed by SuperScript III Reverse transcriptase (Thermo
Fischer Scientific) using 1300 ng purified RNA template.
Real-Time PCR was performed using SYBRGreenMaster
Mix (Thermo Fischer Scientific) on a StepOnePlus™ plat-
form (Thermo Fischer Scientific). Results are expressed as
fold change above no-target crRNA control cells after being
normalized to HPRT1 expression using the Ct method.
All related information is listed in Supplementary File 2.
RESULTS AND DISCUSSION
The four mutations of the RVR and RR variants of As-
Cas12a [S542R, K548V, N552R and K607R, (12)] are com-
bined resulting in the AsCas12a-RVRR variants. The four
mutations at the analogous positions of the RVR and RR
variants of Lb-, Fn- and MbCas12a have also been intro-
duced into the sequences of these three nucleases creat-
ing the corresponding RVRR mutants (Figure 1A and B)
(10,12). Their activities and PAM preferences were com-
pared in the plasmid-based GFxFP assay described previ-
ously (18,24). We prefer this mammalian system for deter-
mining PAMpreferences over bacterial or in vitro selections,
on the one hand, since these nucleases have been reported to
exhibit different PAM preferences when tested in vitro and
in mammalian cells (10). On the other hand, testing mam-
malian genomic targets with various PAMs to reveal the
PAM sequence requirements of RNA-guided nucleases is
burdened with the uncertainties of the varying cleavage ef-
ficiencies of the different target sequences involved. By con-
trast, in the GFxFP system the PAM preferences are tested
on the same spacer sequence, and thus, the differences in the
cleavage activities of nucleases can be more unambiguously
assigned to the PAM sequences examined. Since the PAM
preferences of the Cas12a nucleases show some sequence
dependence (10), in this study we have explored at least four
different targets to establish PAMpreferences that are more
generally valid.
Figure 1C shows a comparison of the activities of the
RVRR variants of all four Cas12a nucleases relative to the
corresponding WT, RVR and RR mutants on targets with
their optimal PAM sequences: TTTC to the WT, TATC
to the RVR and TCTC/TTCC/TCCC to the RR variants
(3,10,12,13,25,26). Introducing the RVRRmutations to As-
and FnCas12a was found to abolish their activity on the
PAMsequences examined. In contrast,Mb- andLbCas12a-
RVRR mutants were found to exhibit considerable activ-
ities, the LbCas12a-RVRR variant being compatible with
most of these PAM sequences, while exhibiting lower ac-
tivity on TCTC PAM (Figure 1C, Supplementary Figures
S1–S4). LbCas12a has further advantages including that
it exhibits the highest activity among these four Cas12a
nucleases in certain experimental systems (10,18,25,27,28).
Furthermore, it remains active at lower temperatures which
makes it the choice of Cas12a nuclease for gene editing and
transcription activations in plant and ectotherm animals
(28–32). Based on these characteristics, we have decided to
subject LbCas12a-RVRR to a deeper investigation.
First, we have analysed the preferences of LbCas12a-
RVRR at all combinations of PAM positions –3 and –1 on
four targets (Figure 2A and B, Supplementary Figure S5).
For clarity, we discuss the results according to four panels
keeping position –3 fix and varying the four possible nu-
cleotides at position –1.
TTTN PAMs: LbCas12a-WT shows robust activity on
its optimal PAM sequences (TTTV, where V is A, C or G)
and lower but considerable activity on TTTT, which is con-
sistent with former reports on LbCas12a disfavouring the
T nucleotide at position -1 (3,10,25,33). The RVRR vari-
ant works with all the four nucleotides including ‘T’ at the
–1 position (TTTN PAM) and shows highest activity with
a –1 ‘A’ nucleotide (TTTA) (Figure 2A, first panel, Supple-
mentary Figure S5).
TATN PAMs: Activity profiling of targets with TATN
PAM sequences has revealed that the RVR mutant demon-
strates robust activity on TATV sequences, while the RVRR
variant shows activity on all the four sequences (TATN
PAM), although its activity is higher with -1 R nucleotides
(TATA and TATG PAMs) (Figure 2A, second panel, Sup-
plementary Figure S5).
TCTN PAMs: As it was previously reported, –3 C in
PAM sequence is disfavoured by theWT and the RVR vari-
ant; however, LbCas12a-RR demonstrates robust activity
with TCTN PAMs (10). The RVRR variant shows moder-
ate activity on TCTV sequences, while its activity is negli-
gible with a –1 ‘T’ (Figure 2A, third panel, Supplementary
Figure S5).
TGTN PAMs: The analysis of the effect of –3 G in PAM
sequence has revealed an unexpectedly high activity of the
RVRR variant of LbCas12a [reaching the highest activity
withM at position -1 (TGTA or TGTC)], whereas the other
variants, i.e. WT, RVR and RR were found to show de-
creased or negligible cleavage efficiencies. No considerable
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Figure 1. Activity of Cas12a variants on targets with candidate PAM sequences measured in the GFxFP assay. (A) Schematics depicting the main features
of the WT and three mutant variants of Cas12a used: each protein sequence is flanked by a nuclear localization signal (NLS) and is preceded by a 3xHA
tag. The RVRR variant combines all the mutations included in RVR and RR Cas12a. (B) Mutations used for RVR and RR variants are listed for all four
Cas12a orthologues in the table (orange – AsCas12a, blue – LbCas12a, green – FnCas12a, yellow – MbCas12a). (C) Average activity of WT As-, Lb-, Fn-
and MbCas12a orthologues and their mutant variants (RVR, RR, RVRR) on four targets with TTTC, TATC, TTCC, TCTC and TCCC PAM sequences,
measured in the GFxFP assay. See also Supplementary Figure S1–4.
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Figure 2. Activity of LbCas12a variants on targets with candidate PAM sequences measured in the GFxFP assay. (A) Average activity of LbCas12a-
WT and its mutant variants (RVR, RR, RVRR) on four targets with TNTN PAM sequences measured in the GFxFP assay (N: A, G, C or T). See also
Supplementary Figure S5. (B) PAMposition -3 base preference of LbCas12a variants. See also Supplementary Figure S5. (C) Average activity of LbCas12a-
WT and its mutant variants (RVR, RR, RVRR) on four targets with additional RR-related (NTCC and NCCC) PAM sequences measured in GFxFP
assay (N: A, G, C or T). See also Supplementary Figures S6 and S7. (D) Average activity of LbCas12a-WT and its mutant variants (RVR, RR, RVRR) on
four targets with additional RVR-related (TANC) PAM sequences measured in the GFxFP assay (N: A, G, C or T). See also Supplementary Figure S8.
(E) Average activity of LbCas12a-WT and its mutant variants (RVR, RR, RVRR) on four targets with additional single PAM base substitutions (NTTC
and TTNC PAM sequences) measured in the GFxFP assay (N: A, G, C or T). See also Supplementary Figures S9 and S10.
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Figure 3. Modifications mediated by the LbCas12a-RVRR variant on targets with candidate PAM sequences. (A) Disruption mediated by the LbCas12a-
RVRR variant on targets with TTTV (WT-related PAMs), TATV, TACV (RVR-related PAMs), TTCV, TCCV, TCTV, CTCV, CCCV (RR-related PAMs),
or TGTV PAM sequences in HEK293.EGFP or HEK293.clover cells (V: A, G or C). The means and interquartile ranges are shown; data points are
plotted as open circles representing the mean of biologically independent triplicates. See also Supplementary Figures S11–S19. (B) Indels mediated by the
LbCas12a-WT and LbCas12a-RVRR variant on human endogenous targets with TTTN (WT-related PAMs), TGTN or TCTN (RR-related PAMs) PAM
sequences in HEK293 cells (N: A, G, C or T). The means and interquartile ranges are shown; data points are plotted as open circles representing the mean
of biologically independent triplicates. See also Supplementary Figures S20–S22.
activity of either the WT or the RVR or RRmutants of Lb-
Cas12a on targets with a ‘G’ nucleotide at PAM position
-3 have been reported in earlier studies (Figure 2A, fourth
panel, Supplementary Figure S5) (12,13).
We have also examined some motifs related to
TTCC/CTCC/TCCC and TAYC PAM sequences on
which RR or RVR LbCas12a variants, respectively, exhibit
some activities (10,12,13). These screens have revealed
three additional PAM motifs on which the RVRR variant
shows robust activity, namely TACC, TTCC and CTCC
PAMS (Figure 2C and D, Supplementary Figures S6–S8).
Inspired by the observation that the RVRRmutant is active
on PAM sequences, on which the former mutants are not,
we have examined their preferences at positions -2 and -4
on NTTC and TTNC PAM motifs. However, no newer
PAM preferences were revealed in these screens, although
the TTTC and TTCC motives of RVRR were confirmed
(Figure 2E, Supplementary Figures S9 and S10).
Altogether, the RVRR variant seems to unite the PAM
preferences of both the WT and the RVR and RR variants
examined, except for the TCTT PAM of the LbCas12a RR
mutant. It demonstrates activity on 15 of the 16 possible
combinations of TNTN PAM sequences, although it pre-
serves a slightly higher preference for a –3 ‘T’ nucleotide
(Figure 2B). Thus, the PAM of the LbCas12a-RVRR vari-
ant resembles the TNTN consensus PAM sequence with a
permissiveness for –2 ‘C’ in some combinations.
The ultimate aim of the development of new variants is
to be applied on genomic target sequences. Here, we aimed
to confirm the above described PAM preferences of the
RVRR variant on genomic targets, although this approach
is plagued by the high variability of the LbCas12a nucle-
ase activities on diverse target sequences. EGFP disruption
has been shown to be a versatile and effective approach to
test the activity of the SpCas9 nuclease, utilizing a copy of
EGFP sequence integrated into the genome (34,35). How-
ever, the rarity of the ‘TTT’ motif strongly limits its ap-
plicability for Cas12a nucleases, since only two targets are
found in the entire EGFP sequence (10,11). To overcome
this limitation, we have generated a HEK293 cell line con-
taining an integrated copy of clover, that is codon optimized
to harbour a great number of TTT motifs for the Cas12a
nucleases.We have determined the disruption activity of the
LbCas12a-RVRRmutant on 98 targets. As shown in Figure
3A, we have categorized the targets according to the PAM
motifs, most of them differing in the –2 and/or –3 positions,
to form groups that are related to the preferences of theWT
or that of the RR or RVRmutants. TGTVPAMs are new to
LbCas12a variants therefore they are categorised as a new,
distinct PAM group.
In line with the observation that Cas12a nucleases are
more ‘pickier’ in their target selection than SpCas9 is
(18,36), LbCas12a-RVRR was found to show a relatively
weak activity on several targets in almost all PAM groups.
The highest activity is evident with the TTTV PAM, and a
moderately higher activity was detected with TAYV, TGTV
TTCV, CCCV and TCCV compared to the CTCV and
TCTV sequences (Figure 3A, Supplementary Figures S11–
S19), a finding consistent with the results obtained in the
GFxFP assay.
To make a meaningful comparison of the activity of the
LbCas12a-WT and the LbCas12a-RVRRmutant we give a
side by side presentation of their indel percentages revealed
by next-generation sequencing separately on 17 targets with
TTTV PAMs that are optimal for the WT protein, as well
as on 5 targets with TTTT PAM sequence on which theWT
protein shows decreased activity (Figure 3B). The RVRR
mutations do not reduce the activity of LbCas12a on tar-
gets with TTTV PAM, but significantly increase its activity
on targets with TTTT PAM, consistent with the PAM pref-
erences discerned in the GFxFP assay (Figures 2A and 3B,
Supplementary Figure S20). We have also compared their
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Figure 4. Genome-wide specificities of the LbCas12a-WT and the LbCas12a-RVRR variant. (A) Off-target sites for the LbCas12a-WT and the LbCas12a-
RVRR variant with seven different crRNAs determined using GUIDE-seq in HEK293 cells. Mismatches compared to the on-target sites are highlighted
in colour, and GUIDE-seq read counts are shown on the right of the on- and off-target sequences representing a measure of cleavage efficiency at a given
site. See also Supplementary File 4. (B) Distribution of the number of base substitutions to the WT-related TTTN PAM sequence of LbCas12a-WT and
LbCas12a-RVRR off-targets.
activities on 18–18 targets with TCTN or TGTN PAMs. As
expected, the mutations increased the indel inducing activ-
ities significantly on targets with TGTV and TGTT PAMs
and slightly on targets with TCTV and TCTT PAMs (Fig-
ure 3B, Supplementary Figures S21 and S22).
We were also curious to see the fidelity of this variant
compared to the WT nuclease, thus conducted GUIDE-
seq genome wide off-target analyses (20) on 7 endoge-
nous targets with TTTV PAM sequence in HEK293 cells.
Five of seven targets had been tested previously, and had
been found to have off-target sites with LbCas12a-WT (27).
Here we revealed that the RVRR variant cleaves at more
off-target sites than the WT nuclease does, except for the
FANCF target 1 (Figure 4A, Supplementary Figure S23A).
While the LbCas12a-WT cleaves off-target sequences typ-
ically having the canonical TTTV PAM or with single T
to C substitutions in its PAM sequence, the RVRR vari-
ant cleaves several additional off-target sites having PAM
sequences differing in up to all three thymidines (Figure 4A
and B, Supplementary Figure S23). This finding is in line
with the more permissive PAM requirements of this mutant
and suggests that the increased off-target propensity is pri-
marily the consequence of the wider sequence space avail-
able to this variant. Nevertheless, if we restrict the compari-
son to the off-target sites of LbCas12a-WT, a slight increase
in the off- versus on-target reads for LbCas12a-RVRR is
discernible (Supplementary Figure S23B).
Regarding the general shortage of TTTV PAMmotifs in
appropriate distances from targeted genomic positions, the
expanded target space offered by the RVRR mutant is es-
pecially advantageous for using it in combination with base
editors (14,37). We have replaced the inactive LbCas12a-
WTwith the inactiveRVRRmutant in the dLbCas12a-WT-
BE construct [(dCpf1-BE) (14)] and have compared their
activities of C to T editing on six endogenous targets. As
expected, the two base editors exhibited similar efficiencies
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Figure 5. Comparison of C to T base editing efficiency of dLbCas12a-WT-BE and dLbCas12a-RVRR-BE inHEK293 cells. C to T base editing efficiency of
dLbCas12a-WT-BE and dLbCas12a-RVRR-BE on six human endogenous targets with TTTV (WT-related PAMs), TATC (RVR-related PAMs), or TCTV
and TCCC (RR-related PAMs) PAM sequences (V: A, G or C). C to T base editing efficiencies were analysed by EditR (19). The position of all candidate
cytosines are shown. GC with red background: a guanine precedes the candidate cytosine. Green background shows the editing window determined by Li
et al. (14). Bars correspond to the average of 3 parallel samples. See also Supplementary Figure S24.
Figure 6. Effect of the D156R mutation on the activity of the LbCas12a-RVRR variant Disruption mediated by the LbCas12a-RVRR and the impLb-
Cas12a variants on targets (A) with TTTV (WT-related PAMs), TCTV, TTCV, TCCV, CCCV (RR-related PAMs), TATV, TACV (RVR-related PAMs) and
TGTV PAM sequences, (B) NTTV PAM sequences with in HEK293.clover cells (V: A, G or C; N: A, G, C or T). Green dots mark the two available targets
with TTTV PAM sequences. The means and interquartile ranges are shown; data points are plotted as open circles representing the mean of biologically
independent triplicates. See also Supplementary Figures S25 and S26.
on the targets with TTTV PAM sequences, while the RVRR
variant showed higher editing on targets with TNTNPAMs
(Figure 5). The C to T edits detected were mostly confined
to the 8 to 13 editing window described for the dLbCas12a-
WT-BE (14); however, we have noticed some exceptions
(Figure 5, FANCF target 35 7C and FANCF target 86 6C).
These results suggest that the dLbCas12a-RVRR-BE vari-
ant preserves the editing activity of the WT variant, but it
is compatible with a broadened target range. We have also
checkedwhether the fidelity of base editingmediated by dL-
bCas12a is altered by RVRR mutations. We have selected
21 predicted off-target sites (38) of the six targets shown
in figure 5 containing up to four mismatches (Supplemen-
tary File 2), and analysed the rates of off-target base editing.
Compared to the dLbCas12a-WT-BE, we have detected no
increase in off-target editing for the RVRR variant on these
sequences (Supplementary Figure S24). These results are in
line with those of the GUIDE-seq analysis, showing minute
differences between the fidelities of the WT and the RVRR
nucleases on targets with canonical TTTV PAM sequences.
While we had been finalizing these analyses, the gener-
ation of AsCas12a variants with similarly loosened PAM
constrains have been reported in an impressive and detailed
study (39). It has been reported that the E174R mutation
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Figure 7. Comparison of the activities of Lb- and AsCas12a variants on targets with various PAM sequences in HEK293.GFP and HEK293.clover
cells. Disruption mediated by the LbCas12a-WT, LbCas12a-RVRR, impLbCas12a and enAsCas12a nucleases on targets (A) with TTTV (WT-related
PAMs) and VTTV PAM sequences, (B) with TAYV (RVR-related PAMs), YYYV (RR-related PAMs) and TGTV PAM sequences in HEK293.clover and
HEK293.GFP cells (V: A, G or C). Means and interquartile ranges are shown; data points are plotted as open circles representing the mean of biologically
independent triplicates. See also Supplementary Figures S27 and S28.
considerably enhances the activity of the AsCas12a variants
to about two-fold of theWT’s activity on targets with TTTV
PAM sequences (39). We have introduced the analogous
mutation (D156R) to LbCas12a-RVRR to create an im-
proved LbCas12a variant (termed impLbCas12a, possess-
ing overall the mutations D156R, G532R, K538V, Y542R
and K595R), and we have tested whether this mutation in
LbCas12a also results in an increased activity. Although
an overall enhancing effect may be discernible in average
(1.3-fold) primarily due to its enhanced activity on TTTV,
TCCV, CCCV, TATC and TACV PAMs (the highest in-
crease being 1.9-fold for TACV and 1.7-fold for TATV), it
lags behind the degree observed in the case of AsCas12a on
targets with TTTV PAM sequences (Figure 6A and Supple-
mentary Figures S25 and S26).
We have also realized that this mutation makes the
AsCas12a variants more permissive for NTTV PAM se-
quences (39), and we have tested the impLbCas12a mu-
tant on targets with NTTV PAMs in the disruption as-
say. The D156R mutation of impLbCas12a seems to fur-
ther broaden the PAM preferences of the variant to include
NTTV PAMmotifs (Figure 6B).
Next, we have compared the activity of enAsCas12a with
that of the LbCas12a-RVRR and the impLbCas12a vari-
ants in disruption assays on 49 GFP and clover targets. We
have focused either on those targets on which LbCas12a-
RVRR exhibited higher activity (i.e. targets with TGTV
PAMs or RR- and RVR-related PAMs) in our previous ex-
periments (Figure 3A) or on those targets that we assumed
to be preferred by enAsCas12a (i.e. targets with VTTV or
TTTVPAMs). This latter PAM-altered variant was selected
to tolerate NTTN PAMs and had an enhanced activity on
TTTV PAMs (39). In line with our former experiments,
and as it is apparent from Figure 7, RVRR mutations have
been found to exert no increasing effect on targets withWT-
related (TTTV) and VTTV PAMs, while greatly increasing
the activity of LbCas12a on targets with TGTV, RR- and
RVR-related PAMs. Addition of the D156R mutation does
not seem to decrease the activity of the RVRR variant on
any PAMs examined; however, it considerably increases its
activity on targets with VTTV and RVR-related PAMs, of-
fering a more versatile and efficient choice of Cas nucle-
ases. Thus, these experiments have confirmed that the ef-
fects of the D156R mutation, namely loosening the PAM
preferences of the Cas12a nuclease at the -4 position and
enhancing its activity in a PAM- and target-dependentman-
ner, seem to be transferable between As- and LbCas12a.
Comparing the activities of the As- and LbCas12a vari-
ants, we have found that impLbCas12a does not surpass
the activity of enAsCas12a on targets with NTTV PAMs
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(Figure 7A and Supplementary Figure S27), but exceeds it
on targets with RR- and RVR-related PAMs (Figure 7B
and Supplementary Figure S28). Since impLbCas12a and
enAsCas12a have partially overlapping but still different
target and PAM preferences (10), they complement each
other, and jointly they considerably increase the target space
available for Cas12a nucleases.
The broadened target space of the LbCas12a variant
developed here allows using multiple targets with different
PAM sequences, which makes it easier to find targets in ap-
propriate positions for transcriptional activation of genes.
Thus, we have tested the inactive impLbCas12a variant in
fusion with 10 consecutive SunTags to recruit transcrip-
tion factors (40) to the promoter of the SPRN locus. We
have used two sets of targets, one with canonical TTTV
PAMs and one with alternative PAMs (Supplementary Fig-
ure S29A and B). As expected, the inactive impLbCas12a-
SunTag variant leveraged the activity of the WT counter-
part with both sets of targets (Supplementary Figure S29).
In summary, the PAM preference of the RVRR mutants
of LbCas12a nuclease unite the PAM motifs on which the
WT, RVR and RR variants demonstrate activities, and also
involve new PAM motifs (TGTN) on which no LbCas12a
variants have been demonstrated to exert substantial ac-
tivities so far. Their target space is considerably broad-
ened, thus the theoretical probability of finding a suitable
PAM for the RVRR variants in DNA sequences increases
to about three-fold compared to the RR variant, which,
until now, has possessed the broadest PAM space among
the LbCas12a nucleases. Our results suggest that the RVRR
mutants offer superior alternatives to the WT, RVR or RR
variants of LbCas12a in many applications, such as mul-
tiplex gene editing, transcriptome modulation, epigenetic
editing and C to T base editing. We have shown that im-
pLbCas12a is a useful alternative for enAsCas12a, owing
to their different activities on various PAM sequences. Fur-
ther advantages of the LbCas12a variants include their
less pronounced temperature dependence compared to the
AsCas12a nucleases, and high activity at lower tempera-
tures (29,31,32). Thus, our findings suggest that the appli-
cation of impLbCas12a is more advantageous than that of
enAsCas12a for ectotherm animals and plants.
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